Your session is about to expire
← Back to Search
Protease Inhibitor
PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19
Phase 2
Waitlist Available
Research Sponsored by Pardes Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1-28
Summary
This trial tests a new antiviral medicine called PBI-0451 (Pomotrelvir) on adults with COVID-19 who have symptoms but are not hospitalized. The medicine aims to stop the virus from multiplying, helping patients recover faster.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1-28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1-28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Virologic Efficacy of PBI-0451 (Pomotrelvir)
Secondary study objectives
Clinical Efficacy of PBI-0451(Pomotrelvir) Versus Placebo Through Study Day 1-28
Clinical Efficacy of PBI-0451(Pomotrelvir) Versus Placebo Through Study Day 28
Effect of PBI-0451(Pomotrelvir) on SARS-CoV-2
+1 moreOther study objectives
Incidence of Rebound SARS-CoV-2 Infection
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PBI-0451 (Pomotrelvir)Experimental Treatment1 Intervention
PBI-0451(Pomotrelvir): 2 x 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
Group II: PlaceboPlacebo Group1 Intervention
PBI-0451(Pomotrelvir): 2 x placebo to match PBI-0451(Pomotrelvir) tablets administered orally twice daily (BID) with food for 5 days (10 total doses)
Find a Location
Who is running the clinical trial?
Pardes Biosciences, Inc.Lead Sponsor
1 Previous Clinical Trials
130 Total Patients Enrolled
David Wilfret, MDStudy DirectorPardes Biosciences